Neumora Therapeutics, Inc. Common Stock
Here’s whether Neumora Therapeutics, Inc. Common Stock (NMRA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +216.3%; 3-month momentum positive (+23.2%); rising volume confirms the move (1.17x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.84% over 10 days); RSI 72 — overbought, elevated pullback risk. Currently 33.1% off its 52-week high. Score: +2/7.
NMRA is holding above its long-term 200-day MA ($2.19) but has slipped below the 50-day MA ($2.59), pointing to short-term weakness in an otherwise intact trend. With an RSI of 72.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +216.3% compares to +27.9% for SPY (beat the market by 188.4%). The current 33.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.